Brand Index Methodology
The Morning Consult Brand Index is an indicator of brand strength among consumers. Each Fortune 500 company receives a score based on a ratio of favorable to unfavorable impressions among U.S. adults and its overall favorability. This ensures that a score takes into account how well-liked a company is among people who have an opinion of it without penalizing companies that are not consumer-facing.
Morning Consult polls thousands of adults across the country each week. The surveys are conducted online using large, established online survey vendors. The data is weighted to approximate a nationally representative sample based on age, race/ethnicity, gender, educational attainment, region, annual household income, home ownership status and marital status.
Merck started 2019 strong, grabbing $10.8 billion in global sales during the first quarter—an 8% increase year-over-year—and raising its full-year revenue range for the year. This builds off the $42.3 billion in global sales the pharmaceutical giant netted in 2018, a 5% increase from 2017. Merck’s blockbuster cancer immunotherapy drug Keytruda continues to shine amongst its portfolio. Accounting for nearly a quarter of the company’s pharmaceutical sales, Keytruda netted $2.3 billion in sales for the first quarter in 2019. Merck is currently looking forward to the results of additional Keytruda studies later this year.
CEO
Kenneth C. Frazier
CEO Title
Chairman, President & Chief Executive Officer
Sector
Health Care
Industry
Pharmaceuticals
HQ Location
Kenilworth, N.J.
Website
Years on Fortune 500 List
65
Employees
69,000
SPONSOR CENTER
| $ millions | % change | |
|---|---|---|
| Revenues ($M) | $42,294 | 5.4% |
| Profits ($M) | $6,220.0 | 159.8% |
| Assets ($M) | $82,637 | |
| Total Stockholder Equity ($M) | $26,701 |
| Profit as % of Revenues | 14.7% | |
| Profits as % of Assets | 7.5% | |
| Profits as % of Stockholder Equity | 23.3% |
| Earnings Per Share ($) | 2.32 | |
| EPS % Change (from 2017) | 166.7% | |
| EPS % Change (5 year annual rate) | 9.6% | |
| EPS % Change (10 year annual rate) | -4.4% |
| Total Return to Investors (2018) | 40.2% | |
| Total Return to Investors (5 year, annualized) | 12.3% | |
| Total Return to Investors (10 year, annualized) | 13.8% |
- Previous Close:
- Market Cap: NaNB
- Next Earnings Date:
- High:
- Low:
- 52 Week High:
- 52 Week Low:
- 52 Week Change %: 0.00
- P/E Ratio: n/a
- EPS:
- Dividend Yield: n/a
News about Merck
Out of more than 100 business sectors, drug companies are in the top 10 of profits.
These 56 companies are on at least four of Fortune's 2018 rankings.
Must-read business news, delivered every morning.
With Congress split between Republicans and Democrats, pharma and biotech stocks are ready to surge.
Must-read business news, delivered every morning.
Quotes delayed at least 15 minutes. Market data provided by Interactive Data. ETF and Mutual Fund data provided by Morningstar, Inc.. Dow Jones Terms & Conditions: http://www.djindexes.com/mdsidx/html/tandc/indexestandcs.html. S&P Index data is the property of Chicago Mercantile Exchange Inc. and its licensors. All rights reserved Terms & Conditions. Powered and implemented by Interactive Data Managed Solutions